Ohta et al. [29] found that PI3K inhibitors enhanced the sensitivity of ovarian cancer to cisplatin by inhibiting p-AKT levels and downstream targets of PI3K/Akt cascades, (such as BAD and NF-κB). This evidence concerns the gene BAD and ovarian carcinoma.